Bacillus Calmette-Guérin vaccine-related complications in children in Oman

Ann Saudi Med. 2021 Jan-Feb;41(1):24-30. doi: 10.5144/0256-4947.2021.24. Epub 2021 Feb 4.

Abstract

Background: Bacillus Calmette-Guérin (BCG) vaccine-related complications are frequently observed in children in Oman. There are a few regional studies on BCG complications, but none from Oman.

Objective: Evaluate the spectrum of BCG-vaccine related complications and immune status in Omani children.

Design: Retrospective cross-sectional study.

Setting: Referral tertiary hospital.

Methods: Children aged younger than 13 years old and with complications of BCG vaccination recorded from 2006-2018 were included in this study. Clinical characteristics, treatment, immune workup and outcome were reviewed from hospital records.

Main outcome measures: Different BCG vaccine-related complications categorized by the site of involvement.

Sample size: 226.

Results: Of the 226 children had BCG-vaccine related complications, 99% received BCG vaccine immediately after birth. The median age of presentation was 4 months. The most common complication was isolated BCG lymphadenitis (85%, n=192), followed by BCG-related osteomyelitis (10.2%, n=23) and disseminated BCG infection (4.9%, n=11). The median age of presentation of disseminated BCG was 5 months, with different organs involved. Out of 11 children with disseminated BCG infection, 72.7% (n=8) had primary immune deficiency (PID), including chronic granulomatous disease (CGD, n=5), severe combined immunodeficiency (SCID) (n=2); 1 patient had Mendelian susceptibility to mycobacterial disease (IFNGR2 deficiency); 2 patients with PID not yet identified and the 1 with a non-specific PID had blood or saliva samples sent for whole-exome sequencing.

Conclusion: Because of the spectrum of BCG vaccine-related complications, including the most severe in children with PID, we suggest that delaying the BCG vaccine from birth to 6 months may prevent disseminated BCG diseases and their complications in children with PID because any PID will have been identified before 6 months. Further studies are needed to guide this recommendation.

Limitations: Single center-based study that may not provide a full overview of all BCG vaccine-related complications in Oman. Unavailability of details of some microbiological results and an inability to determine the detailed management for all patients.

Conflict of interest: None.

MeSH terms

  • Adolescent
  • BCG Vaccine / adverse effects
  • Bacillus*
  • Child
  • Cross-Sectional Studies
  • Humans
  • Infant
  • Mycobacterium bovis*
  • Oman / epidemiology
  • Retrospective Studies

Substances

  • BCG Vaccine

Grants and funding

None.